Diabetes Metab J.  2014 Aug;38(4):261-273. 10.4093/dmj.2014.38.4.261.

A Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor

Affiliations
  • 1Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. jypark@amc.seoul.kr

Abstract

Type 2 diabetes mellitus (T2DM) is a complex endocrine and metabolic disorder, and a major public health problem that is rapidly increasing in prevalence. Although a wide range of pharmacotherapies for glycemic control is now available, management of T2DM remains complex and challenging. The kidneys contribute immensely to glucose homeostasis by reabsorbing glucose from the glomerular filtrate. Sodium-glucose cotransporter 2 (SGLT2) inhibitors, a new class of antidiabetic agents that inhibit glucose absorption from the kidney independent of insulin, offer a unique opportunity to improve the outcomes of patients with T2DM. In this review, we provide an overview of two globally-approved SGLT2 inhibitors, dapagliflozin and canagliflozin, and discuss their effects and safety. This information will help clinicians to decide whether these drugs will benefit their patients.

Keyword

Canagliflozin; Dapagliflozin; Diabetes mellitus, type 2; Glucosuria; SGLT2 inhibitor

MeSH Terms

Absorption
Diabetes Mellitus, Type 2*
Drug Therapy
Glucose
Homeostasis
Humans
Hypoglycemic Agents
Insulin
Kidney
Prevalence
Public Health
Canagliflozin
Glucose
Hypoglycemic Agents
Insulin
Full Text Links
  • DMJ
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr